ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Saturday, November 12, 2022

1:00PM-3:00PM: Abstract Number: 0171

Cardiac Involvement in Idiopathic Inflammatory Myopathies: When Should We Look for It?

Muscle Biology, Myositis and Myopathies Poster I

1:00PM-3:00PM: Abstract Number: 0445

Cardiovascular Burden in Patients with ANCA-Associated and Non-ANCA Associated Vasculitis

Vasculitis – ANCA-Associated Poster I: Epidemiology, Outcomes, and Classification

1:00PM-3:00PM: Abstract Number: 0008

CD11c+ T-Bet+ B Cells Traffic to Human Bone Marrow

B Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

1:00PM-3:00PM: Abstract Number: 0047

Cenerimod, a Novel Selective S1P1 Receptor Modulator, Prevents or Attenuates Joint Inflammation in Several Preclinical Models of Rheumatoid Arthritis

RA – Animal Models Poster

1:00PM-3:00PM: Abstract Number: 0363

Centrally-Acting Angiotensin Converting Enzyme Inhibitor (cACEi) and Angiotensin Receptor Blocker (cARB) Use and Cognitive Dysfunction in Patients with Systemic Lupus

SLE – Treatment Poster I

1:00PM-3:00PM: Abstract Number: 0088

Challenges in the Management of Psoriatic Arthritis in Latin America: A Systematic Review

Healthcare Disparities in Rheumatology Poster

1:00PM-3:00PM: Abstract Number: 0380

Changes in Disease Activity and Patient-Reported Outcomes in Psoriatic Arthritis Patients Treated with Ixekizumab in a Real-World US Cohort

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster I

1:00PM-3:00PM: Abstract Number: 0163

Changes in Juvenile Dermatomyositis After the COVID-19 Pandemic

Muscle Biology, Myositis and Myopathies Poster I

1:00PM-3:00PM: Abstract Number: 0285

Characteristics and Outcomes of Patients with Rheumatoid Arthritis Treated with Upadacitinib in a Global Real-World Setting

RA – Treatment Poster I

1:00PM-3:00PM: Abstract Number: 0296

Characteristics and Treatment-selection in Patients with Rheumatoid Arthritis and with Inadequate Response to Janus Kinase Inhibitors

RA – Treatment Poster I

1:00PM-3:00PM: Abstract Number: 0189

Characteristics Associated with a Positive PEST Screening Among Patients with Psoriasis Without a Diagnosis of Psoriatic Arthritis: Results from the Global Psoriasis and Beyond Study

Patient Outcomes, Preferences, and Attitudes Poster I

1:00PM-3:00PM: Abstract Number: 0438

Characterization of Interstitial Lung Disease in the Presence of Antineutrophil Cytoplasmic Antibodies

Vasculitis – ANCA-Associated Poster I: Epidemiology, Outcomes, and Classification

1:00PM-3:00PM: Abstract Number: 0092

Characterizing Levels of Specialist Care Received by Patients with Systemic Lupus Erythematosus: Clinical Characteristics, Emergency Care, Hospitalization, and Costs Among Commercially-insured Adults in the United States

Healthcare Disparities in Rheumatology Poster

1:00PM-3:00PM: Abstract Number: 0029

Characterizing the Anti-fibrotic Effect of Tofacitinib in TGF-β Stimulated Fibroblast-like Synoviocytes from Patients with OA

Osteoarthritis and Joint Biology – Basic Science Poster

1:00PM-3:00PM: Abstract Number: 0497

Classification Criteria and Existing Pre-Test Probability Stratification Tools Perform Poorly in Diagnosing Giant Cell Arteritis

Vasculitis – Non-ANCA-Associated and Related Disorders Poster I: Giant Cell Arteritis

«Previous Page
1
…
4
5
6
7
8
…
39
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at abstracts@rheumatology.org.